{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:48:20Z","timestamp":1768981700702,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study demonstrates the impact of adjuvant on the development of T follicular helper (Tfh) and B cells, and their influence on antibody responses in mice vaccinated with SARS-CoV-2-spike-ferritin-nanoparticle (SpFN) adjuvanted with either Army Liposome Formulation containing QS-21 (SpFN\u2009+\u2009ALFQ) or Alhydrogel<jats:sup>\u00ae<\/jats:sup>(SpFN\u2009+\u2009AH). SpFN\u2009+\u2009ALFQ increased the size and frequency of germinal center (GC) B cells in the vaccine-draining lymph nodes and increased the frequency of antigen-specific naive B cells. A single vaccination with SpFN\u2009+\u2009ALFQ resulted in a higher frequency of IL-21-producing-spike-specific Tfh and GC B cells in the draining lymph nodes and spleen, S-2P protein-specific IgM and IgG antibodies, and elicitation of robust cross-neutralizing antibodies against SARS-CoV-2 variants as early as day 7, which was enhanced by a second vaccination. This was associated with the generation of high titer, high avidity binding antibodies. The third vaccination with SpFN\u2009+\u2009ALFQ elicited high levels of neutralizing antibodies against the Omicron variant. No cross-neutralizing antibodies against Omicron were induced with SpFN\u2009+\u2009AH. These findings highlight the importance of ALFQ in orchestrating early induction of antigen-specific Tfh and GC B cell responses and long-lived plasma cells in the bone marrow. The early engagement of S-2P specific naive B cells and high titer IgM antibodies shape the development of long-term neutralization breadth.<\/jats:p>","DOI":"10.1038\/s41541-023-00638-6","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:02:46Z","timestamp":1679860966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6276-0791","authenticated-orcid":false,"given":"Shikha","family":"Shrivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua M.","family":"Carmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shraddha","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeshwer S.","family":"Sankhala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3724-9195","authenticated-orcid":false,"given":"Wei-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9664-2232","authenticated-orcid":false,"given":"Phuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-6426","authenticated-orcid":false,"given":"William C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3348-1632","authenticated-orcid":false,"given":"Jocelyn","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Corbitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5767-8870","authenticated-orcid":false,"given":"Sandra","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica S.","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0000-7734","authenticated-orcid":false,"given":"Alexander","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8638-2772","authenticated-orcid":false,"given":"Isabella","family":"Swafford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo D.","family":"Terriquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8014-9291","authenticated-orcid":false,"given":"Hung V.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2900-1667","authenticated-orcid":false,"given":"Jiae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ousman","family":"Jobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-3414","authenticated-orcid":false,"given":"Dominic","family":"Paquin-Proulx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-2373","authenticated-orcid":false,"given":"Gary, R.","family":"Matyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory D.","family":"Gromowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Currier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-8956","authenticated-orcid":false,"given":"Elke","family":"Bergmann-Leitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayvon","family":"Modjarrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson L.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-7232","authenticated-orcid":false,"given":"M. Gordon","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-0302","authenticated-orcid":false,"given":"Allison M. W.","family":"Malloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-4969","authenticated-orcid":false,"given":"Mangala","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,18]]},"reference":[{"key":"638_CR1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.chom.2020.08.002","volume":"28","author":"G Dagotto","year":"2020","unstructured":"Dagotto, G., Yu, J. & Barouch, D. H. Approaches and challenges in SARS-CoV-2 vaccine development. Cell Host Microbe 28, 364\u2013370 (2020).","journal-title":"Cell Host Microbe"},{"key":"638_CR2","unstructured":"World Health Organization. COVID vaccine tracker and landscape. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (2023)."},{"key":"638_CR3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat, F. & Krammer, F. SARS-CoV-2 vaccines: status report. Immunity 52, 583\u2013589 (2020).","journal-title":"Immunity"},{"key":"638_CR4","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.mayocp.2020.07.021","volume":"95","author":"GA Poland","year":"2020","unstructured":"Poland, G. A., Ovsyannikova, I. G., Crooke, S. N. & Kennedy, R. B. SARS-CoV-2 vaccine development: current status. Mayo Clin. Proc. 95, 2172\u20132188 (2020).","journal-title":"Mayo Clin. Proc."},{"key":"638_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381 (2020).","journal-title":"Science"},{"key":"638_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/ijpvm.ijpvm_513_21","volume":"13","author":"SR Pordanjani","year":"2022","unstructured":"Pordanjani, S. R. et al. A Comprehensive Review on Various Aspects of SARS-CoV-2 (COVID-19) Vaccines. Int. J. Prev. Med. 13, 151\u2013162 (2022).","journal-title":"Int. J. Prev. Med."},{"key":"638_CR7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"638_CR8","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"638_CR9","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00356-x","volume":"6","author":"SA Mendonca","year":"2021","unstructured":"Mendonca, S. A., Lorincz, R., Boucher, P. & Curiel, D. T. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines 6, 97 (2021).","journal-title":"NPJ Vaccines"},{"key":"638_CR10","volume":"12","author":"JH Tian","year":"2021","unstructured":"Tian, J. H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372 (2021).","journal-title":"Nat. Commun."},{"key":"638_CR11","first-page":"e936523","volume":"28","author":"DV Parums","year":"2022","unstructured":"Parums, D. V. Editorial: First approval of the protein-based adjuvanted nuvaxovid (NVX-CoV2373) Novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune protection from viral variants. Med. Sci. Monit. 28, e936523 (2022).","journal-title":"Med. Sci. Monit."},{"key":"638_CR12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","volume":"386","author":"V Hall","year":"2022","unstructured":"Hall, V. et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N. Engl. J. Med. 386, 1207\u20131220 (2022).","journal-title":"N. Engl. J. Med."},{"key":"638_CR13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2021.2088","volume":"325","author":"JR Mascola","year":"2021","unstructured":"Mascola, J. R., Graham, B. S. & Fauci, A. S. SARS-CoV-2 viral variants-tackling a moving target. JAMA 325, 1261\u20131262 (2021).","journal-title":"JAMA"},{"key":"638_CR14","doi-asserted-by":"crossref","first-page":"e0297921","DOI":"10.1128\/mbio.02979-21","volume":"13","author":"G McLean","year":"2022","unstructured":"McLean, G. et al. The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines. mBio 13, e0297921 (2022).","journal-title":"mBio"},{"key":"638_CR15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"638_CR16","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. https:\/\/www.who.int\/en\/activities\/tracking-SARSCoV-2-variants\/ (2022). Accessed 14 Jan 2022."},{"key":"638_CR17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"638_CR18","doi-asserted-by":"crossref","first-page":"110143","DOI":"10.1016\/j.celrep.2021.110143","volume":"37","author":"MG Joyce","year":"2021","unstructured":"Joyce, M. G. et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 37, 110143 (2021).","journal-title":"Cell Rep."},{"key":"638_CR19","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00414-4","volume":"6","author":"JM Carmen","year":"2021","unstructured":"Carmen, J. M. et al. SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. NPJ Vaccines 6, 151 (2021).","journal-title":"NPJ Vaccines"},{"key":"638_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00392-7","volume":"6","author":"KM Wuertz","year":"2021","unstructured":"Wuertz, K. M. et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. NPJ Vaccines 6, 129 (2021).","journal-title":"NPJ Vaccines"},{"key":"638_CR21","doi-asserted-by":"crossref","first-page":"e2106433118","DOI":"10.1073\/pnas.2106433118","volume":"118","author":"HAD King","year":"2021","unstructured":"King, H. A. D. et al. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc. Natl. Acad. Sci. USA 118, e2106433118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"638_CR22","doi-asserted-by":"crossref","first-page":"eabi5735","DOI":"10.1126\/scitranslmed.abi5735","volume":"14","author":"MG Joyce","year":"2022","unstructured":"Joyce, M. G. et al. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Sci. Transl. Med. 14, eabi5735 (2022).","journal-title":"Sci. Transl. Med."},{"key":"638_CR23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14760584.2020.1745636","volume":"19","author":"CR Alving","year":"2020","unstructured":"Alving, C. R., Peachman, K. K., Matyas, G. R., Rao, M. & Beck, Z. Army Liposome Formulation (ALF) family of vaccine adjuvants. Expert Rev. Vaccines 19, 279\u2013292 (2020).","journal-title":"Expert Rev. Vaccines"},{"key":"638_CR24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/08982104.2018.1538239","volume":"29","author":"P Singh","year":"2019","unstructured":"Singh, P., Beck, Z., Matyas, G. R. & Alving, C. R. Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition. J. Liposome Res. 29, 247\u2013250 (2019).","journal-title":"J. Liposome Res."},{"key":"638_CR25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.immuni.2019.07.001","volume":"51","author":"JA Roco","year":"2019","unstructured":"Roco, J. A. et al. Class-switch recombination occurs infrequently in germinal centers. Immunity 51, 337\u2013350.e337 (2019).","journal-title":"Immunity"},{"key":"638_CR26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/ni.2019","volume":"12","author":"SL Nutt","year":"2011","unstructured":"Nutt, S. L. & Tarlinton, D. M. Germinal center B and follicular helper T cells: siblings, cousins or just good friends? Nat. Immunol. 12, 472\u2013477 (2011).","journal-title":"Nat. Immunol."},{"key":"638_CR27","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","volume":"53","author":"K Lederer","year":"2020","unstructured":"Lederer, K. et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity 53, 1281\u20131295.e1285 (2020).","journal-title":"Immunity"},{"key":"638_CR28","doi-asserted-by":"crossref","first-page":"eabl5842","DOI":"10.1126\/sciimmunol.abl5842","volume":"6","author":"J Feldman","year":"2021","unstructured":"Feldman, J. et al. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. Sci. Immunol. 6, eabl5842 (2021).","journal-title":"Sci. Immunol."},{"key":"638_CR29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"638_CR30","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/eji.201344313","volume":"44","author":"S Zehentmeier","year":"2014","unstructured":"Zehentmeier, S. et al. Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells. Eur. J. Immunol. 44, 2306\u20132317 (2014).","journal-title":"Eur. J. Immunol."},{"key":"638_CR31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/bloodadvances.2017004481","volume":"1","author":"SF Brynjolfsson","year":"2017","unstructured":"Brynjolfsson, S. F., Mohaddes, M., Karrholm, J. & Wick, M. J. Long-lived plasma cells in human bone marrow can be either CD19(+) or CD19(). Blood Adv. 1, 835\u2013838 (2017).","journal-title":"Blood Adv."},{"key":"638_CR32","doi-asserted-by":"crossref","first-page":"eaal2200","DOI":"10.1126\/sciimmunol.aal2200","volume":"2","author":"LD Williams","year":"2017","unstructured":"Williams, L. D. et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci. Immunol. 2, eaal2200 (2017).","journal-title":"Sci. Immunol."},{"key":"638_CR33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/vaccines10050717","volume":"10","author":"SC Johnston","year":"2022","unstructured":"Johnston, S. C. et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine is protective and promotes a strong immunological response in the Cynomolgus Macaque Coronavirus disease 2019 (COVID-19) Model. Vaccines 10, 717 (2022).","journal-title":"Vaccines"},{"key":"638_CR34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.chom.2021.01.016","volume":"29","author":"SM Townsley","year":"2021","unstructured":"Townsley, S. M. et al. B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. Cell Host Microbe 29, 564\u2013578.e569 (2021).","journal-title":"Cell Host Microbe"},{"key":"638_CR35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10195-z","volume":"10","author":"C Dobano","year":"2019","unstructured":"Dobano, C. et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy. Nat. Commun. 10, 2174 (2019).","journal-title":"Nat. Commun."},{"key":"638_CR36","doi-asserted-by":"crossref","first-page":"eabf1152","DOI":"10.1126\/sciimmunol.abf1152","volume":"6","author":"M Silva","year":"2021","unstructured":"Silva, M. et al. A particulate saponin\/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Sci. Immunol. 6, eabf1152 (2021).","journal-title":"Sci. Immunol."},{"key":"638_CR37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent, A. M. et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev. Vaccines 16, 55\u201363 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"638_CR38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","volume":"16","author":"MB Laurens","year":"2020","unstructured":"Laurens, M. B. RTS,S\/AS01 vaccine (Mosquirix): an overview. Hum. Vaccin Immunother. 16, 480\u2013489 (2020).","journal-title":"Hum. Vaccin Immunother."},{"key":"638_CR39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"638_CR40","first-page":"e00281","volume":"12","author":"OS Adeniji","year":"2021","unstructured":"Adeniji, O. S. et al. COVID-19 severity is associated with differential antibody Fc-mediated innate immune functions. mBio 12, e00281\u201321 (2021).","journal-title":"mBio"},{"key":"638_CR41","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.immuni.2021.08.015","volume":"54","author":"I Ullah","year":"2021","unstructured":"Ullah, I. et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity 54, 2143\u20132158.e2115 (2021).","journal-title":"Immunity"},{"key":"638_CR42","doi-asserted-by":"crossref","first-page":"eabn9243","DOI":"10.1126\/scitranslmed.abn9243","volume":"14","author":"YC Bartsch","year":"2022","unstructured":"Bartsch, Y. C. et al. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci. Transl. Med. 14, eabn9243 (2022).","journal-title":"Sci. Transl. Med."},{"key":"638_CR43","doi-asserted-by":"crossref","first-page":"e0194266","DOI":"10.1371\/journal.pone.0194266","volume":"13","author":"Y Wen","year":"2018","unstructured":"Wen, Y. et al. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. PLoS ONE 13, e0194266 (2018).","journal-title":"PLoS ONE"},{"key":"638_CR44","doi-asserted-by":"crossref","first-page":"e01737","DOI":"10.1128\/JVI.01737-19","volume":"94","author":"A Verma","year":"2020","unstructured":"Verma, A. et al. Impact of Th1 CD4 follicular helper T cell skewing on antibody responses to an HIV-1 vaccine in Rhesus Macaques. J. Virol. 94, e01737\u201319 (2020).","journal-title":"J. Virol."},{"key":"638_CR45","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00407-3","volume":"6","author":"PV Scaria","year":"2021","unstructured":"Scaria, P. V. et al. Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques. NPJ Vaccines 6, 148 (2021).","journal-title":"NPJ Vaccines"},{"key":"638_CR46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","volume":"366","author":"ME Ackerman","year":"2011","unstructured":"Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8\u201319 (2011).","journal-title":"J. Immunol. Methods"},{"key":"638_CR47","doi-asserted-by":"crossref","first-page":"112630","DOI":"10.1016\/j.jim.2019.07.002","volume":"473","author":"S Fischinger","year":"2019","unstructured":"Fischinger, S. et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods 473, 112630 (2019).","journal-title":"J. Immunol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00638-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00638-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00638-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T01:19:31Z","timestamp":1729127971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00638-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00638-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,18]]},"assertion":[{"value":"29 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.R.M. is named as a co-inventor on U.S. patent application 16\/607,917 entitled \u201cCompositions and methods for vaccine delivery.\u201d M.G.J. and K.M. are named as inventors on international patent application WO\/2021\/178971 A1 entitled \u201cVaccines against SARS-CoV-2 and other coronaviruses.\u201d M.G.J. is named as an inventor on international patent application WO\/2018\/081318 and U.S. patent 10,960,070 entitled \u201cPrefusion coronavirus spike proteins and their use. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}